The underlying mechanism is that cisplatin released from PFCR induces tumor cell apoptosis, while ropivacaine upregulates MHC-I in tumor cells and promotes the recognition of tumor cells by CD8+ T cells, which further kills tumor cells (Fig. 5J). This evidence concerns the gene CD8A and neoplasm.